We recently published a list of While Wall Street Naps, These 10 Stocks Run Wild. In this article, we are going to take a ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

The designation allows pharmacists to substitute it for Humira without prescriber approval (per state law), which expands ...

The approval for interchangeability was supported by data from a phase 4 trial that assessed the pharmacokinetics, efficacy, safety, and immunogenicity of Hadlima vs Humira in patients with moderate ...

The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...